Information Statement - All Other (definitive) (def 14c)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14C INFORMATION

Information Statement Pursuant to Section 14(c)

of the Securities Exchange Act of 1934

Check the appropriate box:

¨	Preliminary Information Statement

o	Confidential, for use of the Commission only (as permitted by Rule 14c-5(d)(2))

x	Definitive Information Statement

BRAVATEK SOLUTIONS, INC.

(Name of Registrant as Specified in Charter)

Payment of Filing Fee (Check the appropriate box):

x	No fee required.

o	Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

	1)	Title of each class of securities to which transaction applies:

	2)	Aggregate number of securities to which transaction applies:

	3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):

	4)	Proposed maximum aggregate value of transaction:

	5)	Total fee paid:

o	Fee paid previously with preliminary materials.

o	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	1)	Amount Previously Paid:

	2)	Form, Schedule or Registration Statement No:

	3)	Filing Party:

	4)	Date Filed:

Bravatek Solutions, Inc.

2028 E. Ben White Boulevard

Suite 240-2835

Austin, TX 78741

866-204-6703

June 22, 2018

NOTICE OF STOCKHOLDER ACTION BY WRITTEN CONSENT

Dear Shareholder:

This notice and the accompanying Information Statement are being distributed to the holders of record (the “ Shareholders ”) of the voting capital stock of Bravatek Solutions, Inc., a Colorado corporation (the “ Company ”), as of the close of business on June 1, 2018 (the “ Record Date ”), in accordance with Rule 14c-2 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”) and the notice requirements of the Colorado Business Corporation Act (the “ CBCA ”). The purpose of this notice and the accompanying Information Statement is to notify the Shareholders of actions approved by our Board of Directors (the “ Board ”) and taken by written consent in lieu of a meeting by the holders of a majority of the voting power of our outstanding capital stock as of the Record Date (the “ Written Consent ”).

The Written Consent approved the following actions:

Increasing the number of authorized shares of Common Stock from 10,000,000,000 shares to 10,600,000,000 shares initially, with the Board having discretion to increase the number of authorized shares by an additional 1,000,000,000 thereafter at any time in the future in the Board’s sole discretion (the “ Authorized Share Increase ”).

The Written Consent is the only shareholder approval required to effect the Corporate Actions under the CBCA, our Articles of Incorporation, as amended, or our Bylaws. No consent or proxies are being requested from our shareholders, and our Board is not soliciting your consent or proxy in connection with the Corporate Actions. The Corporate Actions, as approved by the Written Consent, will not become effective until 20 calendar days after the accompanying Information Statement is first mailed or otherwise delivered to the Shareholders. We expect to mail the accompanying Information Statement to the Shareholders on or about June 22, 2018.

Important Notice Regarding the Availability of Information Statement Materials in Connection with this Schedule 14C : We will furnish a copy of this Notice and Information Statement, without charge, to any shareholder upon written request to the address set forth above, Attention: Corporate Secretary.

WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

		Sincerely,

		/s/ Thomas A. Cellucci
		Thomas A. Cellucci, PhD, MBA Chairman & Chief Executive Officer

Bravatek Solutions, Inc.

2028 E. Ben White Boulevard

Suite 240-2835

Austin, TX 78741

866-204-6703

______________

INFORMATION

STATEMENT

_____________

WE ARE NOT ASKING YOU FOR A PROXY, AND YOU ARE REQUESTED NOT TO SEND A PROXY.

INTRODUCTION

This Information Statement advises the shareholders of Bravatek Solutions, Inc. (the “ Company ,” “ we ,” “ our ” or “ us ”) of the approval of the following corporate actions (the “ Corporate Actions ”):

Increasing the number of authorized shares of Common Stock from 10,000,000,000 shares to 10,600,000,000 shares initially, with the Company’s Board of Directors (the “ Board ”) having discretion to increase the number of authorized shares by an additional 1,000,000,000 thereafter at any time in the future in the Board’s sole discretion (the “ Authorized Share Increase ”).

On June 1, 2018 (the “ Record Date ”), our Board of Directors (the “ Board ”) approved the Corporate Actions and submitted the same to certain holders of our Series C Preferred Stock and Series E Preferred Stock. On the same date, the holder of a majority of the voting power of the outstanding capital stock of the Company (the “ Majority Stockholder ”) executed and delivered to us a written consent in lieu of a meeting (the “ Written Consent ”) approving the Corporate Actions.

Section 7-107-104 of the CBCA provides that the written consent of the holders of outstanding shares of voting capital stock having not less than the minimum number of votes which would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted can approve an action in lieu of conducting a special stockholders’ meeting convened for the specific purpose of such action. Section 7-107-104 of the CBCA, however, requires that in the event an action is approved by written consent, a company must provide notice of the taking of any corporate action without a meeting to all shareholders who were entitled to vote upon the action but who have not consented to the action. Under Colorado law, shareholders are not entitled to dissenters’ rights with respect to the Corporate Actions (the “ Stockholders ”).

In accordance with the foregoing, we intend to mail a notice of Written Consent and this Information Statement on or about June 22, 2018. This Information Statement contains a brief summary of the material aspects of the actions approved by the Board and the Majority Stockholder, which holds a majority of the voting capital stock of the Company.

Outstanding Stock

As of June 1, 2018, there were issued and outstanding 8,989,855,924 shares of Common Stock (with the holder of each share having one vote), 0 shares of Series A Preferred Stock, 264,503 shares of Series B Preferred Stock (with the holder of each share having no votes), 319,768 shares of Series C Preferred Stock (with the holder of each share having 10,000 votes), 100,000 shares of Series D Preferred Stock (with the holder of each share having no votes), and 1 share of Series E Preferred Stock (with the holder of that share having 24,375,071,848 votes). Pursuant to Section 7-107-104 of the CBCA, at least a majority of the voting equity of the Company, or at least 18,281,303,887 votes (out of 36,562,607,772 total votes comprised of 8,989,855,924 Common Stock votes, 3,197,680,000 Series C Preferred Stock votes, and 24,375,071,848 Series E Preferred Stock votes), is required to approve the Corporate Actions by written consent. The Majority Stockholder, who holds 223,768 shares of Series C Preferred Stock, and 1 share of Series E Preferred Stock (approximately 72.8% of the total voting equity of the Company), has voted in favor of the Corporate Actions, thereby satisfying the requirement under Section 7-107-104 of the CBCA that at least a majority of the voting equity vote in favor of a corporate action by written consent.

The following table sets forth the name of the Majority Stockholder, the number of shares of Series C Preferred Stock and Series E Preferred Stock held by the Majority Stockholder, the total number of votes that the Majority Stockholder voted in favor of the Authorized Share Increase, and the percentage of the issued and outstanding voting equity of the Company voted in favor thereof.

Name of

Majority Stockholder

Number of Series C Preferred Stock held

Number of Series E Preferred Stock held

Number of Votes held by such Stockholder

Number of Votes that Voted

in favor of the Actions

Percentage of the Voting Equity

that Voted in favor of the Action ⁽¹⁾

Thomas A. Cellucci

223,768

26,612,751,848

72.8

Total

223,768

26,612,751,848

72.8

_______

(1)	Based on 8,989,855,924 shares of Common Stock, and 319,768 shares of Series C Preferred Stock, and 1 share of Series E Preferred Stock considered issued and outstanding as of June 1, 2018, which are the only classes of the Company’s voting securities.

ACTIONS TO BE TAKEN

The Corporate Actions will become effective on the date that we file Certificate(s) of Amendment to the Company’s Articles of Incorporation, as amended, (the “ Amendment(s) ”), with the State of Colorado. We intend to file the Amendments with the State of Colorado promptly after the twentieth (20 ^th ) day following the date on which this Information Statement is mailed to the Stockholders.

INCREASE AUTHORIZED SHARES OF COMMON STOCK

The Board of Directors and the Majority Stockholder of the Company has approved the filing of an amendment to our Articles of Incorporation to increase the number of authorized shares of Common Stock from 10,000,000,000 shares to 10,600,000,000 shares initially, with the Company’s Board of Directors (the “ Board ”) having discretion to increase the number of authorized shares by an additional 1,000,000,000 thereafter at any time in the future in the Board’s sole discretion (the “ Authorized Share Increase ”). The Board of Directors believes these authorized share increases are necessary and advisable in order to maintain our financing and capital raising ability.

The purpose of the increases in authorized Common Stock is to increase the number of shares of our Common Stock available for issuance to investors who provide the Company with funding required to continue operations, and/or to persons in connection with potential acquisition transactions, warrant or option exercises and other transactions under which our Board of Directors may determine are in the best interests of the Company.

The increase in authorized Common Stock will not have any immediate effect on the rights of existing stockholders but will have a dilutive effect on our existing stockholders when additional shares are issued. This increase in the authorized number of shares of Common Stock and any subsequent issuance of such shares could have the effect of delaying or preventing a change in control of the Company without further action by the stockholders. Shares of authorized and unissued Common Stock could (within the limits imposed by applicable law and stock exchange regulations) be issued in one or more transactions which would make a change in control of the Company more difficult, and therefore less likely. Management use of additional shares to resist or frustrate a third-party transaction favored by a majority of the independent stockholders would likely result in an above-market premium being paid in that transaction. Any such issuance of the additional shares of Common Stock would likely have the effect of diluting the earnings per share and book value per share of outstanding shares of Common Stock, and such additional shares could be used to dilute the stock ownership or voting rights of a person seeking to obtain control of the Company. The Board is not aware of any attempt to take control of the Company and has not presented this proposal with the intention that the Authorized Share Increase be used as a type of antitakeover device. Any additional Common Stock, when issued, would have the same rights and preferences as the shares of Common Stock presently outstanding. Any additional Common Stock so authorized will be available for issuance by the Board for stock splits or stock dividends, acquisitions, raising additional capital, conversion of Company debt into equity, stock options, or other corporate purposes. The Company has no other plans for the use of any additional shares of Common Stock. The Company does not anticipate that it would seek authorization from the stockholders for issuance of such additional shares unless required by applicable law or regulations.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following tables set forth certain information regarding the beneficial ownership of our voting securities (Common Stock, Series C Preferred Stock, and Series E Preferred Stock) as of June 1, 2018, of (i) each person known to us to beneficially own more than 5% of our stock, (ii) our directors, (iii) each named executive officer, and (iv) all directors and named executive officers as a group. As of June 1, 2018, there were a total of 8,989,855,924 shares of Common Stock, 319,768 shares of Series C Preferred Stock, and 1 share of Series E Preferred Stock issued and outstanding.

The number of shares beneficially owned is determined under the rules promulgated by the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under those rules, beneficial ownership includes any shares as to which a person or entity has sole or shared voting power or investment power plus any shares which such person or entity has the right to acquire within sixty (60) days of June 1, 2018, through the exercise or conversion of any stock option, convertible security, warrant or other right. Unless otherwise indicated, each person or entity named in the table has sole voting power and investment power (or shares such power with that person’s spouse) with respect to all shares of capital stock listed as owned by that person or entity, and the address of each of the stockholders listed below is: c/o Bravatek Solutions, Inc. 2028 E. Ben White Blvd, Suite 240-2835, Austin, Texas 78741.

Title of Class	Name and Address	Number of Shares Beneficially Owned			Percent of Class ⁽¹⁾
Common Stock	Dr. Thomas A. Cellucci, CEO & Director		895	⁽²⁾	*		%

Common Stock	Debbie King, CFO & Director		30	⁽³⁾	*		%

Common Stock	Chuck Brooks, Director		30	⁽³⁾	*		%

Common Stock	Hans Holmer, Director		30	⁽³⁾	*		%

Common Stock	All Directors and Officers as a Group		985		*		%

Series C Preferred Stock	Dr. Thomas A. Cellucci, CEO & Director		223,768	⁽²⁾		70	%

Series C Preferred Stock	All Directors and Officers as a Group		223,768			70	%

Series E Preferred Stock	Dr. Thomas A. Cellucci, CEO & Director		1			100	%

Series E Preferred Stock	All Directors and Officers as a Group		1			100	%

_________

*Lessthan0.01%

(1)	Applicable percentages of ownership are based on 8,989,855,924 shares of our Common Stock, 319,768 shares of Series C Preferred Stock, and 1 share of our Series E Preferred Stock issued and outstanding as of June 1, 2018, which are the only classes of the Company’s voting securities. Beneficial ownership is determined in accordance with rules of the Securities and Exchange Commission and means voting or investment power with respect to securities. Shares of our Common Stock issuable upon the exercise of stock options exercisable, or convertible securities convertible, currently or within 60 days of June 1, 2018, are deemed outstanding and to be beneficially owned by the person holding such option for purposes of computing such person’s percentage ownership, but are not deemed outstanding for the purpose of computing the percentage ownership of any other person.

(2)	Dr. Cellucci owns -0- shares of Common Stock, however, his Series C Preferred Stock is convertible into 895 shares of Common Stock. Dr. Cellucci has pledged his Series C Preferred Stock as collateral for several notes issued by the Company.

(3)	Includes 30 shares of Common Stock issuable pursuant to vested stock options.

ADDITIONAL INFORMATION

We are subject to the disclosure requirements of the Securities Exchange Act of 1934, as amended, and in accordance therewith, file reports, information statements and other information, including annual and quarterly reports on Form 10-K and 10-Q, respectively, with the Securities and Exchange Commission (the “ SEC ”). Reports and other information filed by the Company can be inspected and copied at the public reference facilities maintained by the SEC at Room 1024, 450 Fifth Street, N.W., Washington, DC 20549. Copies of such material can also be obtained upon written request addressed to the SEC, Public Reference Section, 450 Fifth Street, N.W., Washington, D.C. 20549 at prescribed rates. In addition, the SEC maintains a web site on the Internet (http://www.sec.gov) that contains reports, information statements and other information regarding issuers that file electronically with the SEC through the Electronic Data Gathering, Analysis and Retrieval System.

The following documents, as filed with the SEC by the Company, are incorporated herein by reference:

(1)

Annual Report on Form 10-K for the fiscal year ended March 31, 2017;

(2)

Transition Report on Form 10-KT for the transition period from April 1, 2017, to December 31, 2017;

(3)

Quarterly Report on Form 10-Q for the quarter ended June 30, 2017;

(4)

Quarterly Report on Form 10-Q for the quarter ended September 30, 2017; and

(5)

Quarterly Report on Form 10-Q for the quarter ended March 31, 2018.

You may request a copy of these filings, at no cost, by writing Bravatek Solutions, Inc., 2028 E. Ben White Blvd., Suite 240-2835, Austin, Texas, 78741, or telephoning the Company at (866) 204-6703. Any statement contained in a document that is incorporated by reference will be modified or superseded for all purposes to the extent that a statement contained in this Information Statement (or in any other document that is subsequently filed with the SEC and incorporated by reference) modifies or is contrary to such previous statement. Any statement so modified or superseded will not be deemed a part of this Information Statement except as so modified or superseded.

DELIVERY OF DOCUMENTS TO SECURITY HOLDERS SHARING AN ADDRESS

If hard copies of the materials are requested, we will send only one Information Statement and other corporate mailings to stockholders who share a single address unless we received contrary instructions from any stockholder at that address. This practice, known as “householding,” is designed to reduce our printing and postage costs. However, the Company will deliver promptly upon written or oral request a separate copy of the Information Statement to a stockholder at a shared address to which a single copy of the Information Statement was delivered. You may make such a written or oral request by (a) sending a written notification stating (i) your name, (ii) your shared address and (iii) the address to which the Company should direct the additional copy of the Information Statement, to the Company at 2028 E. Ben White Blvd., Suite 240-2835, Austin, Texas, 78741, or telephoning the Company at (866) 204-6703.

If multiple stockholders sharing an address have received one copy of this Information Statement or any other corporate mailing and would prefer the Company to mail each stockholder a separate copy of future mailings, you may mail notification to, or call the Company at, its principal executive offices. Additionally, if current stockholders with a shared address received multiple copies of this Information Statement or other corporate mailings and would prefer the Company to mail one copy of future mailings to stockholders at the shared address, notification of such request may also be made by mail or telephone to the Company’s principal executive offices.

This Information Statement is provided to the holders of Common Stock of the Company only for information purposes in connection with the Actions, pursuant to and in accordance with Rule 14c-2 of the Exchange Act. Please carefully read this Information Statement.

By Order of the Board of Directors

/s/ Thomas Cellucci

Thomas A. Cellucci, PhD, MBA

Chairman & Chief Executive Officer

Dated: June 19, 2018